Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more
Lyra Therapeutics Inc (LYRA) - Total Assets
Latest total assets as of September 2025: $43.71 Million USD
Based on the latest financial reports, Lyra Therapeutics Inc (LYRA) holds total assets worth $43.71 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lyra Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Lyra Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lyra Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lyra Therapeutics Inc's total assets of $43.71 Million consist of 64.9% current assets and 35.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Lyra Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lyra Therapeutics Inc's current assets represent 64.9% of total assets in 2024, a decrease from 98.3% in 2018.
- Cash Position: Cash and equivalents constituted 61.2% of total assets in 2024, down from 94.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lyra Therapeutics Inc Competitors by Total Assets
Key competitors of Lyra Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lyra Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lyra Therapeutics Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lyra Therapeutics Inc is currently not profitable relative to its asset base.
Lyra Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 3.64 | 15.54 |
| Quick Ratio | 2.43 | 3.64 | 15.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.54 Million | $ 39.49 Million | $ 71.03 Million |
Lyra Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Lyra Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -53.5% |
| Total Assets | $66.35 Million |
| Market Capitalization | $182.85K USD |
Valuation Analysis
Below Book Valuation: The market values Lyra Therapeutics Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lyra Therapeutics Inc's assets decreased by 53.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lyra Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Lyra Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $66.35 Million | -53.47% |
| 2023-12-31 | $142.60 Million | +29.67% |
| 2022-12-31 | $109.97 Million | +100.43% |
| 2021-12-31 | $54.87 Million | -32.12% |
| 2020-12-31 | $80.83 Million | +440.20% |
| 2019-12-31 | $14.96 Million | -41.00% |
| 2018-12-31 | $25.36 Million | -- |